{
    "clinical_study": {
        "@rank": "115963", 
        "arm_group": [
            {
                "arm_group_label": "Tranexamic acid (TXA)", 
                "arm_group_type": "Active Comparator", 
                "description": "1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure."
            }, 
            {
                "arm_group_label": "\u03b5-Aminocaproic Acid (EACA)", 
                "arm_group_type": "Active Comparator", 
                "description": "7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure."
            }
        ], 
        "brief_summary": {
            "textblock": "Tranexamic acid (TXA) and \u03b5-aminocaproic acid (EACA) are two drugs shown to limit blood loss\n      following major surgery, from cardiac to orthopedic procedures. Yet compared to tranexamic\n      acid (TXA), research on the clinical impact of \u03b5-aminocaproic acid (EACA) in total knee\n      arthroplasty (TKA) is limited. The primary aim of this study is to determine whether TXA and\n      EACA provide similar blood decreasing effects following TKA or whether one drug provides a\n      superior effect over the other in reducing patients' blood loss."
        }, 
        "brief_title": "Clinical Efficacy of Tranexamic Acid and \u03b5-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis", 
        "condition_browse": {
            "mesh_term": "Osteoarthritis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Persons aged 18 - 90 years who are scheduled to undergo a unilateral total knee\n             replacement surgery\n\n        Exclusion Criteria:\n\n          -  Non-English speaking individuals\n\n          -  Individuals with a history of deep vein thrombosis or pulmonary embolism    within\n             one year\n\n          -  Individuals with a history of coagulopathy\n\n          -  Heart stent within one year\n\n          -  Pre-operative autologous blood donation\n\n          -  Unwilling or unable to take Coumadin for deep vein thrombosis (DVT) prophylaxis\n\n          -  Received nonsteroidal anti-inflammatory drug (NSAID) or platelet antiaggregant\n             treatment within five days prior to surgery\n\n          -  Pre-operative creatinine greater than 1.5mg/dL"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "372", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01873768", 
            "org_study_id": "MOS-16735", 
            "secondary_id": "MOS1316735"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tranexamic acid (TXA)", 
                "description": "1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.", 
                "intervention_name": "Tranexamic Acid (TXA)", 
                "intervention_type": "Drug", 
                "other_name": "Cyklokapron"
            }, 
            {
                "arm_group_label": "\u03b5-Aminocaproic Acid (EACA)", 
                "description": "7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.", 
                "intervention_name": "\u03b5-Aminocaproic Acid (EACA)", 
                "intervention_type": "Drug", 
                "other_name": "Amicar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "6-Aminocaproic Acid", 
                "Antifibrinolytic Agents", 
                "Tranexamic Acid", 
                "Fibrin Modulating Agents"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Tranexamic acid", 
            "6-Aminocaproic Acid", 
            "Arthroplasty", 
            "Osteoarthritis", 
            "Arthritis", 
            "Joint Diseases", 
            "Musculoskeletal Diseases", 
            "Rheumatic Diseases", 
            "Antifibrinolytic Agents", 
            "Fibrin Modulating Agents", 
            "Pharmacologic Actions", 
            "Coagulants", 
            "Therapeutic Uses"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "location": {
            "contact": {
                "email": "ckb@millerortho.com", 
                "last_name": "Clifford K Boese, MD", 
                "phone": "712-323-5333"
            }, 
            "contact_backup": {
                "email": "lcenteno@millerortho.com", 
                "last_name": "Leslie Centeno, BA", 
                "phone": "712-388-0144"
            }, 
            "facility": {
                "address": {
                    "city": "Council Bluffs", 
                    "country": "United States", 
                    "state": "Iowa", 
                    "zip": "51503"
                }, 
                "name": "Miller Orthopedic Specialists"
            }, 
            "investigator": {
                "last_name": "Clifford K Boese, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Trial of Tranexamic Acid and \u03b5-Aminocaproic Acid to Reduce Blood Loss Following Total Knee Arthroplasty", 
        "overall_contact": {
            "email": "ckb@millerortho.com", 
            "last_name": "Clifford K Boese, MD", 
            "phone": "712-323-5333"
        }, 
        "overall_contact_backup": {
            "email": "lcenteno@millerortho.com", 
            "last_name": "Leslie Centeno", 
            "phone": "712-388-0144"
        }, 
        "overall_official": {
            "affiliation": "Miller Orthopedic Specialists", 
            "last_name": "Clifford K Boese, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Transfusion rate", 
            "safety_issue": "No", 
            "time_frame": "1.5 to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01873768"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Miller Orthopedic Specialists", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Alegent Creighton Health Mercy Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Creighton University School of Medicine", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Miller Orthopedic Specialists", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}